Biogen price target raised to $340 from $315 at Mizuho

Mizuho analyst Salim Syed raised the firm’s price target on Biogen to $340 from $315 and keeps a Buy rating on the shares. The analyst updated the firm’s model post the Q1 results. The analyst now estimates Ocrevus worldwide peak sales of $8B in 2025, up from $7.5B previously.